Floatz Rating
BB68/100
Confidence
Indicative
Sponsor
Fujian Cancer Hospital
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
70High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07581834CT.gov Efficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical Study | — | Recruiting | — | — | — |
NCT07174336CT.gov A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) | — | Recruiting | — | — | — |
NCT06235931CT.gov A Clinical Study of Darcilil Combined With AI Combined With Pyrrotinib in the Treatment of TPBC | — | Recruiting | — | — | — |
NCT05514054CT.gov A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT04707196CT.gov A Study of Abemaciclib in Indian Women With Advanced Breast Cancer | — | Completed | — | — | — |
NCT04113863CT.gov Evaluation of ATRA Activity in Combination With Anastrozole in Pre-operative Phase of Operable Early Breast Cancer | — | Terminated | — | — | — |
NCT03304080CT.gov Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HR-positive, HER2-positive Metastatic Breast | — | Active Not Recruiting | — | — | — |
NCT03272477CT.gov Study to Compare Neoadjuvant Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy and Quality of Life Assessment Under Adjuvant Therapy in Operable HER2+/HR+ Breast Cancer Patients | — | Completed | — | — | — |
NCT03220178CT.gov Impact of eHealth-support on Quality of Life in Metastatic Breast Cancer Patients Treated With Palbociclib and Endocrine Therapy | — | Terminated | — | — | — |
NCT03099174CT.gov This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer | — | Completed | — | — | — |
Show 8 more trialsShow fewer
NCT03024580CT.gov A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast Cancer | — | Unknown | — | — | — |
NCT02476786CT.gov Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score | — | Recruiting | — | — | — |
NCT02970682CT.gov SFX-01 in the Treatment and Evaluation of Metastatic Breast Cancer | — | Completed | — | — | — |
NCT02057133CT.gov A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread | — | Active Not Recruiting | — | — | — |
NCT01723774CT.gov PD 0332991 and Anastrozole for Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT01262274CT.gov Randomized Phase II Trial of Anastrozole Plus Metronomic Tegafur-uracil as Neo-adjuvant Therapy in Postmenopausal Breast Cancer | — | Terminated | — | — | — |
NCT01151215CT.gov Study of Anastrozole +/- AZD8931 in Postmenopausal Women With Endocrine Therapy Naive Breast Cancer | — | Terminated | — | — | — |
NCT00005908CT.gov Primary Chemotherapy With Docetaxel-Capecitabine and Doxorubicin-Cyclophosphamide in Breast Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Breast Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Anastrozole (this asset) | Fujian Cancer Hospital | Approved | BB · 68 |
| Tamoxifen | Eli Lilly and Company | P3 | BB |
| Adriamycin | Merck Sharp & Dohme LLC | P4 | BB |
| Letrozole | Fujian Cancer Hospital | P4 | BB |
| Docetaxel | Universitas Airlangga | P4 | BB |
| Exemestane | Fujian Cancer Hospital | P4 | BB |
| Cyclophosphamide | Merck Sharp & Dohme LLC | P4 | BB |
| Palbociclib | Eli Lilly and Company | P4 | BB |
| Microporous Polysaccharide Hemospheres | Fundación para la Investigación del Hospital Clínico de Valencia | P4 | BB |
+42 more in the Breast Neoplasm cohort
Other indications for Anastrozole
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hormone Receptor-Positive Breast Cancer | — | P4 | BBB · 74 |
| Hypogonadotropic Hypogonadism | — | P4 | BBB · 73 |
| Female Breast Carcinoma | — | P4 | BBB · 72 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Anastrozole in Breast Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/anastrozole-breast-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →